A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 38,363 shares of NTLA stock, worth $468,795. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,363
Previous 38,421 0.15%
Holding current value
$468,795
Previous $859,000 8.27%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$19.72 - $27.36 $1,143 - $1,586
-58 Reduced 0.15%
38,363 $788,000
Q2 2024

Jul 19, 2024

BUY
$20.02 - $27.22 $17,577 - $23,899
878 Added 2.34%
38,421 $859,000
Q1 2024

Apr 22, 2024

BUY
$23.82 - $32.8 $31,394 - $43,230
1,318 Added 3.64%
37,543 $1.03 Million
Q4 2023

Jan 16, 2024

BUY
$23.16 - $32.34 $98,545 - $137,606
4,255 Added 13.31%
36,225 $1.1 Million
Q3 2023

Oct 24, 2023

BUY
$31.62 - $45.78 $176,249 - $255,177
5,574 Added 21.12%
31,970 $1.01 Million
Q2 2023

Jul 25, 2023

BUY
$34.58 - $46.03 $79,672 - $106,053
2,304 Added 9.56%
26,396 $1.08 Million
Q1 2023

Apr 14, 2023

BUY
$33.3 - $44.82 $28,704 - $38,634
862 Added 3.71%
24,092 $897,000
Q4 2022

Feb 08, 2023

SELL
$33.21 - $62.69 $81,464 - $153,778
-2,453 Reduced 9.55%
23,230 $810,000
Q3 2022

Oct 25, 2022

SELL
$53.92 - $71.7 $1,995 - $2,652
-37 Reduced 0.14%
25,683 $1.44 Million
Q2 2022

Aug 12, 2022

SELL
$38.49 - $76.21 $17,743 - $35,132
-461 Reduced 1.76%
25,720 $1.33 Million
Q1 2022

May 11, 2022

SELL
$58.27 - $118.99 $678,787 - $1.39 Million
-11,649 Reduced 30.79%
26,181 $1.9 Million
Q4 2021

Feb 08, 2022

BUY
$100.76 - $138.36 $284,243 - $390,313
2,821 Added 8.06%
37,830 $4.47 Million
Q3 2021

Nov 02, 2021

BUY
$132.37 - $176.78 $49,374 - $65,938
373 Added 1.08%
35,009 $4.7 Million
Q2 2021

Aug 11, 2021

SELL
$60.88 - $161.91 $127,604 - $339,363
-2,096 Reduced 5.71%
34,636 $5.61 Million
Q1 2021

May 14, 2021

BUY
$46.59 - $83.68 $595,932 - $1.07 Million
12,791 Added 53.43%
36,732 $2.95 Million
Q4 2020

Feb 12, 2021

BUY
$18.83 - $63.53 $158,322 - $534,160
8,408 Added 54.13%
23,941 $1.3 Million
Q3 2020

Nov 04, 2020

SELL
$17.47 - $24.93 $1.01 Million - $1.44 Million
-57,820 Reduced 78.82%
15,533 $309,000
Q2 2020

Jul 17, 2020

BUY
$11.14 - $22.87 $696,550 - $1.43 Million
62,527 Added 577.56%
73,353 $1.54 Million
Q1 2020

Apr 21, 2020

SELL
$9.44 - $15.58 $18,068 - $29,820
-1,914 Reduced 15.02%
10,826 $132,000
Q4 2019

Feb 12, 2020

BUY
$10.43 - $17.67 $132,878 - $225,115
12,740 New
12,740 $187,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $929M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.